TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25056151

Group type: EXPERIMENTAL
Intervention: Immediate therapy group receiving physical therapy (maximum of 12 sessions of 30 min for a 6-week program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed therapy group (6 weeks delay before starting therapy)
Number of subjects: 0
Study: 22033354

Group type: EXPERIMENTAL
Intervention: Quasi-long pulse and Q-switched Nd:YAG laser treatment with topically applied carbon suspension
Number of subjects: 22
Study: 20576793

Group type: EXPERIMENTAL
Intervention: Homozygous for the variant allele of rs12757998 (AA)
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Missense mutations R462Q and D541E
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1286
Study: 18035092

Group type: EXPERIMENTAL
Intervention: HFRC (heart failure patient-specific quality-of-care report cards)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 265
Study: 16518704

Group type: EXPERIMENTAL
Intervention: 330GG genotype
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 330TT genotype
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Reduction of -330G allele frequency
Number of subjects: 382
Study: 12390708

Group type: EXPERIMENTAL
Intervention: rhEGF ophthalmic solution
Number of subjects: 36

Group type: COMPARATOR
Intervention: Drug vehicle (control)
Number of subjects: 36
Study: 9702646

Group type: EXPERIMENTAL
Intervention: Psychological preparation (demonstration of materials, use of a doll, or a book with photographs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Psychological preparation
Number of subjects: 60
Study: 7737255

Group type: EXPERIMENTAL
Intervention: Castration plus nilutamide
Number of subjects: 270

Group type: COMPARATOR
Intervention: Casodex (ICI 176,334) monotherapy
Number of subjects: 270
Study: 2913777

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30617417

Group type: EXPERIMENTAL
Intervention: Water at 2 °C
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water at 37 °C
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water at 60 °C
Number of subjects: 11
Study: 29650341

Group type: EXPERIMENTAL
Intervention: Dietary Diversity Score (DDS)
Number of subjects: 300
Study: 28222543

Group type: EXPERIMENTAL
Intervention: Anodal cerebellar tDCS (2 mA for 10 minutes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cathodal cerebellar tDCS (2 mA for 10 minutes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham cerebellar tDCS (2 mA for 10 minutes)
Number of subjects: 14
Study: 25218922

Group type: EXPERIMENTAL
Intervention: DCCT/EDIC time-weighted hemoglobin A1c
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Time-weighted hemoglobin A1c
Number of subjects: 639
Study: 23810377

Group type: EXPERIMENTAL
Intervention: mFOLFOX-6 combined with bevacizumab and MetMAb
Number of subjects: 0

Group type: COMPARATOR
Intervention: mFOLFOX-6 combined with bevacizumab and placebo
Number of subjects: 0
Study: 21487640

Group type: EXPERIMENTAL
Intervention: CPAP (10 cmH2O for 30 minutes)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 19466247

Group type: EXPERIMENTAL
Intervention: Duofluorid XII (2.92% fluorine, calcium fluoride + 2.71% fluorine, sodium fluoride)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Duraphat (2.26% fluorine, sodium fluoride)
Number of subjects: 7
Study: 16699276

Group type: EXPERIMENTAL
Intervention: Cascabel chilli (3 g daily, 880 ppm capsaicin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ancho chilli (3 g daily, 488 ppm capsaicin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both kinds of chilli
Number of subjects: 12
Study: 15297049

Group type: EXPERIMENTAL
Intervention: Hexavalent outer membrane vesicle (OMV) vaccine (HexaMen) containing six different porin A (PorAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hexavalent outer membrane vesicle (OMV) vaccine (HexaMen)
Number of subjects: 0
Study: 11299084

Group type: EXPERIMENTAL
Intervention: High trans alpha-linolenic acid diet
Number of subjects: 88

Group type: COMPARATOR
Intervention: Low trans alpha-linolenic acid diet
Number of subjects: 88
Study: 9279176

Group type: EXPERIMENTAL
Intervention: Acetate (0 to 14.2 mmol/kg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard parenteral nutrition
Number of subjects: 58
Study: 7867679

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acrivastine 16 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acrivastine 24 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg + pseudoephedrine 60 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2770251

Group type: EXPERIMENTAL
Intervention: Elementary school social skills/peer pressure resistance curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 779391

Group type: EXPERIMENTAL
Intervention: Pethidine (1 mg/kg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anileridine (0.25 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 31236587

Group type: EXPERIMENTAL
Intervention: Voriconazole-resistant IA
Number of subjects: 129

Group type: COMPARATOR
Intervention: Voriconazole-susceptible IA
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Voriconazole-resistant IA (non-ICU)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Voriconazole-susceptible IA (non-ICU)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Voriconazole-resistant IA (ICU)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Voriconazole-susceptible IA (ICU)
Number of subjects: 129
Study: 28237860

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 74

Group type: COMPARATOR
Intervention: α glucosidase inhibitor (αGI)
Number of subjects: 74
Study: 24894652

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg), Trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), Docetaxel (100 mg/m2 initially, later amended to 75 mg/m2) every three weeks for six cycles
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bevacizumab, Trastuzumab, and Docetaxel
Number of subjects: 26
Study: 23131911

Group type: EXPERIMENTAL
Intervention: Honey barrier cream
Number of subjects: 31

Group type: COMPARATOR
Intervention: Zinc oxide ointment
Number of subjects: 31
Study: 20977443

Group type: EXPERIMENTAL
Intervention: Video education on portable video devices
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional verbal instructions
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 84
Study: 18607857

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 15751004

Group type: EXPERIMENTAL
Intervention: Encapsulated warfarin (2.5 mg tablets)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonencapsulated warfarin (2.5 mg tablets)
Number of subjects: 18
Study: 12028870

Group type: EXPERIMENTAL
Intervention: Elective stenting using the heparin-coated beStent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study: 10598553

Group type: EXPERIMENTAL
Intervention: Folic acid administered orally at 25 mg/m2 and 125 mg/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetitive oral administration of folic acid every 6 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetitive oral administration of folic acid
Number of subjects: 0
Study: 7695464

Group type: EXPERIMENTAL
Intervention: Low-dose warfarin
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 10000

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 10000
Study: 2165860

Group type: EXPERIMENTAL
Intervention: Spectinomycin (2-gm single dose)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Co-trimoxazole (two tablets twice daily for seven days)
Number of subjects: 343
Study: 722696

Group type: EXPERIMENTAL
Intervention: Intrauterine progesterone contraceptive system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo systems releasing no hormone
Number of subjects: 24
Study: 31150916

Group type: EXPERIMENTAL
Intervention: Brazil nut intake (1 Brazil nut per day, approximately 1261 μg/Se) for 2 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no Brazil nut intake) for 2 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison of women with MetS (n=23) vs. women without MetS (n=31)
Number of subjects: 54
Study: 27726029

Group type: EXPERIMENTAL
Intervention: Cogstate computerized battery assessment during the first month of induction chemotherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein)
Number of subjects: 34
Study: 25431345

Group type: EXPERIMENTAL
Intervention: Ventricular tachyarrhythmias (VTA) occurring in the morning hours
Number of subjects: 1790
Study: 24249817

Group type: EXPERIMENTAL
Intervention: Probiotic combination (Bifidobacterium infantis, Streptococcus thermophilus, and Bifidobacterium lactis, 1 × 10(9) total organisms)
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 1099
Study: 21661431

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) before surgical resection (Group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Direct surgical resection of HCC (Group B)
Number of subjects: 72
Study: 19628361

Group type: EXPERIMENTAL
Intervention: Low-risk group (<=3 pts)
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Med-risk group (4-7 pts)
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: High-risk group (>=8 pts)
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Comparison to PIII derivation set
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Comparison to PIII validation set
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Comparison to retrospective multicenter validation set
Number of subjects: 1166
Study: 16766321

Group type: EXPERIMENTAL
Intervention: Specialised cognitively accessible interface
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard Windows CE interface
Number of subjects: 32
Study: 15574615

Group type: EXPERIMENTAL
Intervention: Paraprofessional visits
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Nurse visits
Number of subjects: 735

Group type: COMPARATOR
Intervention: Control
Number of subjects: 735
Study: 11382657

Group type: EXPERIMENTAL
Intervention: High-flavonoid (HF) diet enriched with onions and black tea
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-flavonoid (LF) diet
Number of subjects: 32
Study: 9416458

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Losigamone (LSG)
Number of subjects: 10
Study: 8297946

Group type: EXPERIMENTAL
Intervention: Etomidate in lipid emulsion (Etomidat‐Lipuro)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Etomidate in propylene glycol (Hypnomidate)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 232
Study: 3562890

Group type: EXPERIMENTAL
Intervention: one cycle of combination chemotherapy + radiation therapy + 5 cycles of combination chemotherapy
Number of subjects: 237
Study: 30124758

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 147
Study: 27100124

Group type: EXPERIMENTAL
Intervention: LGB-affirmative psychotherapy (10-session individual intervention)
Number of subjects: 54
Study: 24684153

Group type: EXPERIMENTAL
Intervention: Well-child visits with a behavioral health provider
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard well-child visit
Number of subjects: 94
Study: 22943819

Group type: EXPERIMENTAL
Intervention: C.E.R.A. once every 4 weeks by subcutaneous administration
Number of subjects: 253

Group type: COMPARATOR
Intervention: EPO 1-3 times weekly
Number of subjects: 253
Study: 20551967

Group type: EXPERIMENTAL
Intervention: SMOFlipid fat emulsion (omega-3 fatty acids)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard fat emulsion (Intralipid)
Number of subjects: 38
Study: 18386580

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) combined with chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy (CTF regimen)
Number of subjects: 60
Study: 15769240

Group type: EXPERIMENTAL
Intervention: Warning of response verification present
Number of subjects: 0

Group type: COMPARATOR
Intervention: No warning of response verification
Number of subjects: 0
Study: 12940840

Group type: EXPERIMENTAL
Intervention: real-rTMS (suprathreshold 5-Hz, 2000 pulses once a day for 10 consecutive days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: sham-rTMS
Number of subjects: 36
Study: 20287462

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 23
Study: 8856584

Group type: EXPERIMENTAL
Intervention: Serum IL-6 levels in patients with Crohn's disease
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Serum IL-2R levels in patients with Crohn's disease
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Serum IL-6 levels in moderate/severe Crohn's disease
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Serum IL-2R levels in moderate/severe Crohn's disease
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation of IL-6 with ESR
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation of IL-2R with ESR
Number of subjects: 41
Study: 1503928

Group type: EXPERIMENTAL
Intervention: Children with common ALL, WBC 10-50 x 10(9) 1-1, aged 18 months or older
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall cohort of children under 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children with WBC under 10 x 10(9) 1-1
Number of subjects: 0
Study: 6517248

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopyrronium
Number of subjects: 0
Study: 31474458

Group type: EXPERIMENTAL
Intervention: Omadacycline (450 mg orally every 24 h for 48 h then 300 mg orally every 24 h for 7-14 days)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 735

Group type: COMPARATOR
Intervention: Linezolid (600 mg orally every 12 h for 7-14 days)
Number of subjects: 735
Study: 31264623

Group type: EXPERIMENTAL
Intervention: Smaller range of stimulus onset asynchronies
Number of subjects: 51

Group type: COMPARATOR
Intervention: Larger range of stimulus onset asynchronies
Number of subjects: 51
Study: 27069426

Group type: EXPERIMENTAL
Intervention: Harmonic Technique (HT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: End Range Loading (ERL)
Number of subjects: 14
Study: 24499441

Group type: COMPARATOR
Intervention: LET 2.5 mg/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: LET 2.5 mg/day + ZOL 4 mg every 4 weeks (total of 7 infusions)
Number of subjects: 168
Study: 21656079

Group type: EXPERIMENTAL
Intervention: Post-event weeks following celebrity suicides
Number of subjects: 27605
Study: 19745216

Group type: EXPERIMENTAL
Intervention: 15 microg of hemagglutinin antigen by intramuscular injection
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 30 microg of hemagglutinin antigen by intramuscular injection
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 15 microg and 30 microg doses after the second dose
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 15 microg and 30 microg doses
Number of subjects: 240
Study: 17513662

Group type: EXPERIMENTAL
Intervention: Neck extension (5 mL of contrast injected)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Neck flexion (5 mL of contrast injected)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Neutral position (5 mL of contrast injected)
Number of subjects: 42
Study: 14759294

Group type: EXPERIMENTAL
Intervention: Intranasal administration of buserelin
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: s.c. administration of buserelin
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophin (HMG)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with 225 IU per day of either HMG or rFSH
Number of subjects: 195
Study: 11361157

Group type: EXPERIMENTAL
Intervention: Postmenopausal estrogen-progestin replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ongoing randomized clinical trials
Number of subjects: 0
Study: 9571968

Group type: EXPERIMENTAL
Intervention: 5'-DFUR 600 mg/body/day with radiotherapy and SPG (20 mg twice/week or 40 mg/week)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 5'-DFUR 800 mg/body/day with radiotherapy and SPG (20 mg twice/week or 40 mg/week)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination therapy of radiotherapy, 5'-DFUR and SPG
Number of subjects: 33
Study: 7917580

Group type: EXPERIMENTAL
Intervention: 20 mg alendronate daily for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg alendronate daily for 6 months
Number of subjects: 20
Study: 3046406

Group type: EXPERIMENTAL
Intervention: Birch pollen extracts alone
Number of subjects: 53

Group type: COMPARATOR
Intervention: Patient-tailored extracts of birch, alder, and hazel pollen
Number of subjects: 53
Study: 31709734

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PLEX)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: IVMP followed by PLEX
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: PLEX alone
Number of subjects: 97
Study: 29578620

Group type: EXPERIMENTAL
Intervention: APCI settings derived from multivariate linear models for trolox
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: APCI settings derived from multivariate linear models for BHT
Number of subjects: 30

Group type: COMPARATOR
Intervention: APCI settings for tocochromanols
Number of subjects: 30
Study: 27180680

Group type: EXPERIMENTAL
Intervention: Dairy milk (2 or 4 servings, 473 and 946 ml)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Rice beverage (control)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water (473 ml)
Number of subjects: 11
Study: 25477459

Group type: EXPERIMENTAL
Intervention: Summer jobs program
Number of subjects: 1634
Study: 23732465

Group type: EXPERIMENTAL
Intervention: Mucosectom
Number of subjects: 48

Group type: COMPARATOR
Intervention: Flush knife
Number of subjects: 48
Study: 20157835

Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy (QoLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 40
Study: 18374426

Group type: EXPERIMENTAL
Intervention: Virtual task with 3 rewards
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Virtual task with 5 rewards
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Virtual task with 7 rewards
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Virtual task (all conditions)
Number of subjects: 63
Study: 15480852

Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Creatine (6.75 g/d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 16
Study: 12005142

Group type: EXPERIMENTAL
Intervention: Astra Tech implants
Number of subjects: 66

Group type: COMPARATOR
Intervention: Brånemark System implants
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 66
Study: 10493319

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride 1.5 g/d
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride 3.75 g/d
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride 3.0 g/d
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 8725997

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg thrice weekly
Number of subjects: 19
Study: 1782952

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium chloride (80 mmol.24 h‐1)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 7261665

Group type: EXPERIMENTAL
Intervention: 400 mg sulindac per day
Number of subjects: 32

Group type: COMPARATOR
Intervention: 1200 mg ibuprofen per day
Number of subjects: 32
Study: 30501541

Group type: EXPERIMENTAL
Intervention: Telephone Counseling Exercise (TCE)
Number of subjects: 51
Study: 27471899

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with anterior chamber maintainer (Group B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Trabeculectomy (Group A)
Number of subjects: 78
Study: 25632091

Group type: COMPARATOR
Intervention: Expensive placebo (subcutaneous novel injectable dopamine agonist placebo)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cheap placebo (subcutaneous novel injectable dopamine agonist placebo)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cheap placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 12
Study: 23617608

Group type: EXPERIMENTAL
Intervention: NOS‐TBI
Number of subjects: 0
Study: 21785002

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (TUS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study: 19592632

Group type: EXPERIMENTAL
Intervention: Insulin therapy (premeal insulin aspart)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Insulin and Repaglinide (in patients with IGT)
Number of subjects: 100